Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) reported Q4 earnings with a loss of $(1.13) per share, missing the $(0.87) estimate by 29.89%, but saw a 93.8% improvement from last year's $(18.24) loss. Sales of $515.03K exceeded estimates by 32.06%, despite a 64.06% decrease from last year's $1.43M.
March 15, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ensysce Biosciences reported a Q4 loss per share of $(1.13), missing estimates, but sales of $515.03K beat expectations, showing significant improvement from last year.
The mixed results with a miss on EPS but a beat on sales could lead to neutral short-term stock price movement. The significant improvement from last year's losses indicates progress, but the miss on EPS estimates may concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100